Evidence map›Paper›PMID 31593010›Full record

ArticlePancreas2019

Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture.

Yoshihisa Matsushita, Barbara Smith, Michael Delannoy, Maria A Trujillo, Peter Chianchiano, Ross McMillan, Hirohiko Kamiyama, Hong Liang, Elizabeth D Thompson, Ralph H Hruban and 4 more

Abstract read
In one paragraph

Article in Pancreas, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Reversible chemoresistance of pancreatic cancer grown as spheroids.Journal of chemotherapy (Florence, Italy) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yoshihisa MatsushitaFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
Barbara SmithDepartment of Cell Biology, Johns Hopkins University School of Medicine.
Michael DelannoyDepartment of Cell Biology, Johns Hopkins University School of Medicine.
Maria A TrujilloFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
Peter ChianchianoFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
Ross McMillanDepartment of Oncology, Johns Hopkins University School of Medicine.
Hirohiko KamiyamaFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
Hong LiangFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
Elizabeth D ThompsonFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
Ralph H HrubanFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
William MatsuiDepartment of Oncology, Johns Hopkins University School of Medicine.
Laura D WoodFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
Nicholas J RobertsFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.
James R EshlemanFrom the Department of Pathology, Johns Hopkins University School of Medicine, The Sol Goldman Pancreatic Cancer Research Center.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
TARGETING EXTRACELLULAR MATRIX-CANCER STEM CELL INTERACTIONS IN PANCREATIC CANCERR01CA193887 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI MATSUI, WILLIAM H · 2016 to 2021
$1.8M
MENTORING AND RESEARCH IN CANCER STEM CELLSK24CA198315 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI MATSUI, WILLIAM H · 2016 to 2020
$933k
Integrative Analyses to Identify Pancreatic Cancer Susceptibility GenesR00CA190889 · NCI · JOHNS HOPKINS UNIVERSITY · PI ROBERTS, NICHOLAS JASON · 2017 to 2019
$747k
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
Integrative Analyses to Identify Pancreatic Cancer Susceptibility GenesK99CA190889 · NCI · JOHNS HOPKINS UNIVERSITY · PI ROBERTS, NICHOLAS JASON · 2015 to 2016
$172k
NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR003098NCI NIH HHS K24 CA198315NCI NIH HHS K99 CA190889NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R00 CA190889NCI NIH HHS R01 CA193887NCRR NIH HHS S10 RR026824
6 · The paper itself

Abstract

objectivePancreatic ductal adenocarcinoma (PDAC) is the third most common cause of cancer death in the United States. Improved characterized models of PDAC are needed for drug screening.

methodsWe grew 4 established pancreatic cancer cell lines in hanging drop cultures to produce spheroids. We also grew organoids from explanted xenografted PDAC and surgically resected primary PDAC. We performed transmission and scanning electron microscopy and compared findings with those of the normal pancreatic duct. We also performed single-cell cloning to determine the potential options for differentiation.

resultsSpheroids contained tight junctions and desmosomes but lacked zymogen granules, as expected. The former features were present in normal pancreatic duct but absent from PDAC cell lines grown in standard 2-dimensional culture. Spheroids functionally excluded macromolecules in whole mounts. Cells on the surface of PDAC spheroids were carpeted by microvilli except for rare cells with prominent stereocilia. Carpets of microvilli were also seen in low passage organoids produced from xenografts and surgically resected human PDAC, in addition to normal human pancreatic duct. We performed single-cell cloning and resulting spheroids produced both cell phenotypes at the same approximate ratios as those from bulk cultures.

conclusionsPancreatic cancer spheroids/organoids are capable of biphenotypic differentiation.

Indexed as

AnimalsCarcinoma, Pancreatic DuctalCell Culture TechniquesCell DifferentiationCell Line, TumorCell ProliferationDesmosomesFemaleHeterograftsHumansMice, NudeMicroscopy, Electron, ScanningMicroscopy, Electron, TransmissionOrganoidsPancreatic DuctsPancreatic Neoplasms

Identifiers

PMID31593010
PMCPMC6791773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.